Journal: PLOS One
Article Title: An ex vivo functional biomarker of treatment response in pediatric low-grade glioma
doi: 10.1371/journal.pone.0331423
Figure Lengend Snippet: (a) RAS-MAPK pathway demonstrating the effects of the BRAF:KIAA 1549 fusion and targeted therapy with dabrafenib and trametinib. (b) Western blot of BRAF:KIAA 1549 + pLGG-1 cells seeded on organotypic brain slice cultures and treated with trametinib. (c) Western blot of BRAF:KIAA 1549 + pLGG-1 cells seeded on OBSCs and treated with dabrafenib. (d) Heatmap of trametinib treatment-induced protein levels of pMEK, tMEK, pERK, and tERK after 24 and 72 hours. (e) Heatmap of dabrafenib treatment-induced protein levels of pMEK, tMEK, pERK, and tERK after 24 and 72 hours. (f) Heatmap of normalized band intensities (pERK/tERK and pMEK/tMEK) for trametinib treatment at 24 h and 72 h. (g) Heatmap of normalized band intensities (pERK/tERK and pMEK/tMEK) for dabrafenib treatment at 24 h and 72 h.
Article Snippet: We first tested the reproducible engraftment and survival of all three pLGG tumor tissues on SLiCE, which uses living organotypic brain slice cultures (OBSCs) from P8 Sprague-Dawley rat pups as living tissue substrates on which to engraft and treat patient tumor tissues.
Techniques: Western Blot, Slice Preparation